Anchor Capital Advisors LLC Sells 8,418 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Anchor Capital Advisors cut its Regeneron stake by 81.7% in the second quarter, selling 8,418 shares and retaining 1,880 shares worth approximately $1.17 million.
• Regeneron reported strong quarterly results, with EPS of $14.29 and revenue of $4.29 billion, exceeding analyst estimates; revenue increased 16.7% year over year.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and an average price target of $800.36; the company also declared a quarterly dividend of $0.94 per share.

Anchor Capital Advisors LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 81.7% during the second quarter, according to its most recent filing with the SEC. The fund owned 1,880 shares of the biopharmaceutical company's stock after selling 8,418 shares during the quarter. Anchor Capital Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $1,172,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in REGN. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $29,000. Finally, Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $29,000. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $800.36.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $827.72 on Tuesday. The company has a market capitalization of $85.22 billion, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.62 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $859.34. The business's fifty day moving average is $742.21 and its 200 day moving average is $719.75. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm's revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $12.81 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.